CDK4 and small cell lung carcinoma: As a competitive CDK4/6 inhibitor, it reversibly induces G1 cell cycle arrest, protecting hematopoietic lineages from chemotherapy-induced DNA damage and reducing the incidence of single-lineage and multilineage Grade ≥3 CIM in ES-SCLC patients (9–11).